Advertisement

Topics

Dimension Therapeutics Commences Patient Dosing In Global, Multi-Center Phase I/II Clinical Trial Of DTX301 In Ornithine Transcarbamylase (OTC) Deficiency

20:00 EDT 30 Aug 2017 | BioSpace

  Life Sciences Jobs   ...

Original Article: Dimension Therapeutics Commences Patient Dosing In Global, Multi-Center Phase I/II Clinical Trial Of DTX301 In Ornithine Transcarbamylase (OTC) Deficiency

NEXT ARTICLE

More From BioPortfolio on "Dimension Therapeutics Commences Patient Dosing In Global, Multi-Center Phase I/II Clinical Trial Of DTX301 In Ornithine Transcarbamylase (OTC) Deficiency"

Quick Search
Advertisement